New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
09:00 EDTRTRXRetrophin falls 8.1%
Retrophin is down 8.1%, or 96c, to $10.85
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
12:36 EDTRTRXOn The Fly: Top stock stories at midday
Subscribe for More Information
08:01 EDTRTRXRetrophin agrees to sell Pediatric PRV to Sanofi
Retrophin (RTRX) announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (SNY). Retrophin received the Pediatric PRV when Cholbam was approved by the U.S. FDA for the treatment of pediatric and adult patients suffering from bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders. Upon closing of the transaction, Retrophin will receive a payment of $150M, followed by two equal installments of $47.5M in 2016 and 2017. The company will receive a total consideration of $245M in cash from Sanofi in exchange for the Pediatric PRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. The transaction is subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
May 22, 2015
09:26 EDTRTRXRetrophin management to meet with Leerink
Subscribe for More Information
May 15, 2015
10:29 EDTRTRXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
10:01 EDTRTRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:18 EDTRTRXRetrophin initiated with an Outperform at Avondale
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use